Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week’s episode takes a scalpel to the biotech industry’s biggest headlines and exposes the structural reality underneath. What looks like a boom, 100% tariff threats, $170B M&A frenzies, and record-speed drug approvals, is, on closer inspection, a system under pressure. We break down how tariff policy is really a negotiation tool that disproportionately squeezes smaller biotechs, why the GLP-1 obesity race is being decided by adherence and manufacturing economics rather than headline efficacy, and how Big Pharma’s acquisition binge is less confidence and more patent-cliff-driven desperation. At the same time, accelerated approvals are pushing safety risk into the post-market phase, clinical trial infrastructure is quietly breaking down, and regulatory fragmentation is making commercialization increasingly unpredictable. The throughline is simple: the surface narrative suggests strength, but the underlying mechanics point to fragility, deferred risk, and a more volatile biotech landscape ahead
📣🎙️ TODAY’S PODCAST:
[ 00:34 ] Illusion of regulatory authority cracks
[ 01:28 ] Industry masterclass in illusion
[ 02:42 ] 100 percent tariff shock narrative
[ 05:15 ] Policy uncertainty paralyzes development
[ 06:24 ] Obesity drugs gold rush begins
[ 07:11 ] Simulated efficacy vs real world
[ 08:56 ] Manufacturing economics decide winners
[ 10:47 ] 50 days approval speed tradeoff
[ 12:00 ] Severe liver damage and deaths
[ 14:16 ] M&A frenzy driven by patent cliffs
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
